Stockreport

U.S. FDA Grants BRUKINSA® (Zanubrutinib) Accelerated Approval in Relapsed or Refractory Marginal Zone Lymphoma

BeiGene, Ltd. - American Depositary Shares  (BGNE) 
Last beigene, ltd. - american depositary shares earnings: 3/2 04:05 pm Check Earnings Report
PDF This marks the third FDA approval for BRUKINSA and first approval in marginal zone lymphomaTwenty percent of patients achieved complete remission with single-agent BRUKI [Read more]